Literature DB >> 12227459

Neurotransmitter metabolites in CSF: an external quality control scheme.

C Bräutigam1, C Weykamp, G F Hoffmann, R A Wevers.   

Abstract

We report an international external quality control scheme on neurotransmitter metabolites in cerebrospinal fluid (CSF). The neurotransmitter metabolites homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) are analysed to diagnose inborn errors of neurotransmitter metabolism. HVA is the catabolite of dopamine; 5-HIAA is the catabolite of serotonin; and MHPG is the catabolite of noradrenaline. In the first phase, 12 laboratories from six countries participated in this special quality control scheme to define the present state of the art and achieve harmonization in analytical outcome and interpretation. In the second part, recoveries, dilutions and methods for sample preparation were compared. The results of 3 of 12 laboratories were excluded because of unacceptable intralaboratory coefficients of variations (CV) for HVA and/or 5-HIAA. The inter- and intralaboratory CVs, the linearity and the recovery were acceptable for the other laboratories for both parameters. Unacceptable differences in the reference ranges between laboratories, leading to differences in interpretation of the results, became obvious. There was a significant improvement of the interlaboratory CV for HVA after standardization with a calibrator. The reproducibility of MHPG measurement appeared to be adequately established in only two laboratories and recovery was low in all five measuring this metabolite. The quality control scheme is an invaluable tool for controlling the analytical outcome and providing support to laboratories to improve their quality.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12227459     DOI: 10.1023/a:1016550324235

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  11 in total

1.  Differential diagnosis of disorders of biogenic amines metabolism.

Authors:  N Blau; G F Hoffmann
Journal:  Eur J Paediatr Neurol       Date:  1998       Impact factor: 3.140

Review 2.  Inborn errors of pterin metabolism.

Authors:  N Blau
Journal:  Annu Rev Nutr       Date:  1988       Impact factor: 11.848

3.  Biochemical hallmarks of tyrosine hydroxylase deficiency.

Authors:  C Bräutigam; R A Wevers; R J Jansen; J A Smeitink; J F de Rijk-van Andel; F J Gabreëls; G F Hoffmann
Journal:  Clin Chem       Date:  1998-09       Impact factor: 8.327

Review 4.  A review of biochemical and molecular genetic aspects of tyrosine hydroxylase deficiency including a novel mutation (291delC).

Authors:  R A Wevers; J F de Rijk-van Andel; C Bräutigam; B Geurtz; L P van den Heuvel; G C Steenbergen-Spanjers; J A Smeitink; G F Hoffmann; F J Gabreëls
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

5.  Aromatic L-amino acid decarboxylase deficiency: an extrapyramidal movement disorder with oculogyric crises.

Authors:  G C Korenke; H J Christen; K Hyland; D H Hunneman; F Hanefeld
Journal:  Eur J Paediatr Neurol       Date:  1997       Impact factor: 3.140

6.  Cerebrospinal fluid concentrations of pterins and metabolites of serotonin and dopamine in a pediatric reference population.

Authors:  K Hyland; R A Surtees; S J Heales; A Bowron; D W Howells; I Smith
Journal:  Pediatr Res       Date:  1993-07       Impact factor: 3.756

7.  Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis.

Authors:  K Hyland; R A Surtees; C Rodeck; P T Clayton
Journal:  Neurology       Date:  1992-10       Impact factor: 9.910

8.  Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A.

Authors:  H G Brunner; M Nelen; X O Breakefield; H H Ropers; B A van Oost
Journal:  Science       Date:  1993-10-22       Impact factor: 47.728

9.  Congenital dopamine-beta-hydroxylase deficiency. A novel orthostatic syndrome.

Authors:  A J Man in 't Veld; F Boomsma; P Moleman; M A Schalekamp
Journal:  Lancet       Date:  1987-01-24       Impact factor: 79.321

Review 10.  Cerebrospinal fluid investigations for neurometabolic disorders.

Authors:  G F Hoffmann; R A Surtees; R A Wevers
Journal:  Neuropediatrics       Date:  1998-04       Impact factor: 1.947

View more
  3 in total

Review 1.  Monoamine neurotransmitter disorders--clinical advances and future perspectives.

Authors:  Joanne Ng; Apostolos Papandreou; Simon J Heales; Manju A Kurian
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

2.  Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study.

Authors:  Manju A Kurian; Yan Li; Juan Zhen; Esther Meyer; Nebula Hai; Hans-Jürgen Christen; Georg F Hoffmann; Philip Jardine; Arpad von Moers; Santosh R Mordekar; Finbar O'Callaghan; Evangeline Wassmer; Elizabeth Wraige; Christa Dietrich; Timothy Lewis; Keith Hyland; Simon Heales; Terence Sanger; Paul Gissen; Birgit E Assmann; Maarten E A Reith; Eamonn R Maher
Journal:  Lancet Neurol       Date:  2010-11-25       Impact factor: 44.182

3.  The Utility of CSF for the Diagnosis of Primary and Secondary Monoamine Neurotransmitter Deficiencies.

Authors:  A B Burlina; A Celato; G Polo; C Edini; A P Burlina
Journal:  EJIFCC       Date:  2017-03-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.